191
Participants
Start Date
October 2, 2020
Primary Completion Date
January 18, 2024
Study Completion Date
March 25, 2024
Pegloticase with MTX
Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period
Long Island Arthritis & Osteoporosis Care, Babylon
Altoona Center for Clinical Research, Duncansville
MD Medical Research, Oxon Hill
Research Carolina Elite, Denver
PMG Research of Salisbury, LLC, Salisbury
Shelby Clinical Research, LLC, Shelby
Cape Fear Arthritis Care, Leland
PMG Research of Hickory, LLC, Hickory
LIFE Clinical Trials, Margate
Napa Research Center, Pompano Beach
GCP Clinical Research, Tampa
D&H National Research Centers, Miami
Prohealth Research Center, Doral
D&H Tamarac Research Centers, Tamarac
IRIS Research and Development, LLC, Plantation
ClinPro Research Solutions, Tampa
ForCare Clinical Research, Tampa
Bradenton Research Center, Bradenton
University of Alabama at Birmingham, Birmingham
Chattanooga Research & Medicine PLLC (CHARM), Chattanooga
Velocity Clinical Research Cincinnati, Cincinnati
MedPharmics, LLC, Metairie
Abigail Rebecca Neiman, MD, PA, Houston
Pioneer Research Solutions Inc - Houston, Houston
University of Colorado Division of Rheumatology, Aurora
Denver Arthritis Clinic, Denver
Velocity Clinical Research, Salt Lake City, West Jordan
Arizona Arthritis & Rheumatology Research, Phoenix
Arthritis & Rheumatology Research, Mesa
Arizona Arthritis & Rheumatology Research, Gilbert
Santa Fe Rheumatology, Santa Fe
Providence Saint John's Health Center, Santa Monica
Medvin Clinical Research, Tujunga
Amicis Research Center, Northridge
Medvin Clinical Research, Thousand Oaks
Medvin Clinical Research, Covina
Western Washington Medical Group, Bothell
Arthritis Northwest, Spokane
Orthopedic Physicians Alaska, Anchorage
Lead Sponsor
Amgen
INDUSTRY